Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/B Acute Lymphoblastic Leukemia With T(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia With T(9;22)(q34.1;q11.2); BCR-ABL1

16

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 is an emerging landscape with 16 programs across 11 companies. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

15/100

Mech. Concentration

13/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical2

Inotuzumab Ozogamicin

Wyeth-Lederle Vaccines

Mercaptopurine

Stason

Phase 11

Asciminib

Novartis

Phase 27

Rituximab

Roche

Vincristine

Eli Lilly

Doxorubicin

Pfizer

Etoposide

Avyxa

Filgrastim

Eastern Cooperative Oncology Group

Phase 36

Cyclophosphamide

Baxter Healthcare Corporation

Cytarabine

Teva

Dexamethasone

Aspen Global Incorporated

Methotrexate

Jazz Pharmaceuticals

Blinatumomab

Amgen

Approved

No programs

Analysis

Modality Breakdown

16programs

Small molecule956%

Protein / enzyme425%

Monoclonal antibody213%

Antibody–drug conjugate16%

Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%

Not yet recruiting1 · 20%

Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

Pilot Study of Asciminib as a Maintenance Treatment Post Cellular Therapies in Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Recruiting·CCity of Hope Medical Center·Phase 1·NCT07040982·30 enrolled

A Phase 1 Study of Asciminib-Based Induction Therapy in Newly Diagnosed Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Not yet recruiting·CCity of Hope Medical Center·Phase 1·NCT07914166·21 enrolled

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT04530565·348 enrolled

Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT07224100·33 enrolled

Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT01371630·276 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)